Problem

Clinicians must make high-stakes decisions at the point of care, often while navigating a large and fragmented body of peer-reviewed medical literature. The core pain is the time, effort, and risk involved in finding relevant evidence, judging its quality, and translating it into a usable clinical answer. The economic burden is primarily expensive clinician time and the potential cost of delayed or poorly informed decisions.

The killer use case is a doctor facing a specific patient-care question and needing a fast, evidence-based answer during the clinical encounter rather than manually searching multiple journals, guidelines, and reference systems.

Product / Service

OpenEvidence is an AI copilot and medical search engine for healthcare professionals. It organizes and synthesizes peer-reviewed research and other clinical content into evidence-based insights for clinical decision support, with access through its website. Its content includes full-text clinical material, figures, tables, and multimedia, and the company cites relationships with major sources such as NEJM, JAMA, The Lancet, NCCN, Wiley, and Cochrane.

The service is free for verified U.S. healthcare professionals, making it a low-friction point-of-care tool rather than a product restricted to institutional buyers. Its backend ingests data, orchestrates models, and handles core business logic on Google Cloud, while the frontend is delivered through a scalable web application. The intended benefit is to reduce the time required to retrieve and synthesize trustworthy evidence while helping clinicians make better-informed decisions.

Market

OpenEvidence competes in medical AI, clinical decision support, and professional medical-information platforms. Its competitive set includes established evidence and reference products such as Wolters Kluwer’s UpToDate Expert AI, EBSCO’s Dyna AI, and Elsevier’s ClinicalKey AI, as well as newer or adjacent AI tools including Glass Health, Amazon Connect Health, Heidi Evidence, and DeepEvidentia.

The company appears to have substantial commercial traction rather than being pre-launch: OpenEvidence reports more than 200 million AI-powered clinical consultations from U.S. doctors and other frontline clinicians and describes itself as the most widely used medical AI among verified U.S. clinicians. It also announced a $210 million financing round at a $3.5 billion valuation. The available evidence does not disclose revenue or profitability, so its revenue status cannot be determined from these sources, but usage and financing indicate significant adoption and investor validation.